EarnoReview
PAVmed

PAVmed Q3 earnings analysis: EsoGuard Medicare payments begin

PAVmed's preliminary third-quarter results show $1.2 million of EsoGuard revenue at Lucid Diagnostics, a $1.2 million adjusted loss and $8.9 million of cash.

Nov 13, 20263 min read
Laboratory equipment in a diagnostics lab
Laboratory equipment in a diagnostics lab. Image: Zeev Stein ( זאב שטיין) via wikimedia (CC BY 2.5)

The news

PAVmed Inc. (NASDAQ: PAVM) reported preliminary third-quarter 2026 results on Friday, together with a business update across its subsidiaries Lucid Diagnostics, Veris Health and Octeris Medical. The company held a webcast at 8:30 a.m. Eastern the same day. The central item is that Lucid Diagnostics has secured Medicare reimbursement for its EsoGuard esophageal DNA test and began receiving Medicare payments in October.

Lucid submits claims for tests performed at its Texas laboratory to Novitas, the Medicare Administrative Contractor with jurisdiction over that lab, and is paid at EsoGuard’s established Clinical Laboratory Fee Schedule rate. The company is focusing its commercial effort on at-risk Medicare beneficiaries, who it says represent about 50% of the 30 million patients that professional society guidelines recommend for esophageal precancer testing.

In the third quarter Lucid performed 2,871 EsoGuard tests and recognized $1.2 million of revenue. October was a record month, with more than 1,800 tests. The company also announced publication of an 11,991-patient real-world EsoGuard study in the journal Diagnostics, which it describes as the largest peer-reviewed study of nonendoscopic esophageal precancer testing so far.

The financial results are preliminary. Operating expenses for the three months ended September 30 were about $6.8 million, including $1.0 million of stock-based compensation, and the non-GAAP adjusted net loss was about $1.2 million, or $0.19 per share. A year earlier the non-GAAP adjusted loss was about $0.4 million, or $0.62 per share. PAVmed held $8.9 million in cash and cash equivalents, including $5.3 million of restricted cash, at September 30, up from $1.5 million, including $0.3 million restricted, at December 31, 2025.

Our analysis

The figure to separate is revenue from reimbursement. The $1.2 million recognized in the third quarter came before Medicare payments began in October, so the quarter predates the payments. Volume of more than 1,800 tests in October alone is already more than 60% of the 2,871 tests performed in all three months of the third quarter, a pace that, if sustained, would change the revenue line, though a single month is a small sample.

The reported loss was larger than the adjusted one. PAVmed’s as-reported net loss for the quarter was about $11.7 million, compared with $5.4 million a year earlier, and the reconciliation shows a $10.0 million non-cash charge for a change in the fair value of equity method investments. The adjusted measure removes that item and others, which is why management emphasizes it, but the gap is a reminder that non-cash fair value changes can move reported results independently of operations.

The other subsidiaries are at earlier stages. Veris Health reached design freeze for its implantable physiological monitor and began a 90-day animal study in October, keeping it on track for an FDA 510(k) submission in early 2027. Monthly patient enrollment at OSU-The James nearly doubled between July and September. PortIO had an initial FDA meeting in late October and has an in-person pre-submission meeting set for January 2027. Octeris completed a next-generation imaging probe and expects to submit its initial FDA pre-submission package this month, with enrollment in a University of North Carolina validation study expected to begin in January 2027.

Room for disagreement

Optimists will point to the Medicare reimbursement milestone, which Chairman and CEO Lishan Aklog called “a critical and transformational milestone” and said lets PAVmed, as Lucid’s largest common shareholder, benefit directly from Lucid’s near-term revenue opportunity. A more cautious view is that PAVmed’s cash of $8.9 million, of which $5.3 million is restricted, leaves little room against quarterly operating expenses of $6.8 million, and that its development programs all depend on FDA steps that have not yet occurred.

The adjusted loss per share also needs context. The per-share loss fell from $0.62 to $0.19 even though the dollar adjusted loss rose, because the non-GAAP share count is about 6.6 million, compared with about 0.7 million a year earlier.

What to watch

The key data points are EsoGuard test volume and revenue in the fourth quarter, now that Medicare payments are flowing, and the rate at which claims convert to cash. On the pipeline side, the dates to track are Octeris’ pre-submission package this month, the PortIO pre-submission meeting and the start of the North Carolina study in January 2027, and Veris Health’s 510(k) submission in early 2027. Cash will remain an item to follow until the revenue ramp is visible.

Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.

Related